Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Preclinical studies indicate OP-1 is effective three days after stroke

Nov. 16, 1998

SB team attempts to identify the source of antiparkinsonian activity of SKF-83959

Nov. 13, 1998

Neurobiological Technologies initiates phase IIb trial of memantine

Nov. 13, 1998

SCRAS presents new series of NOS and lipid peroxidation inhibitors

Nov. 13, 1998

Ligand and Elan finalize strategic alliance

Nov. 13, 1998

SB-205553 used to investigate role of 5-HT2C receptor antagonists in PD therapy

Nov. 13, 1998

SPBN: a free radical scavenger with potential in pediatric head trauma

Nov. 12, 1998

Pharmacological profile of the novel, selective kappa-opioid agonist HZ2

Nov. 12, 1998

Preparation and use of new CNS-active series reported by Pharmacia & Upjohn

Nov. 12, 1998

Improved dosage form of selegiline now on the U.K. market

Nov. 11, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...